A pilot study to evaluate 3′-deoxy-3′- 18F- fluorothymidine PET for initial and early response imaging in mantle cell lymphoma

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1898-1902

  Herrmann, Ken ^a   Buck, Andreas K ^a,b   Schuster, Tibor ^c   Rudelius, Martina ^a   Wester, Hans Jürgen ^a   Graf, Nicolas ^a   Scheuerer, Christine ^a   Peschel, Christian ^a   Schwaiger, Markus ^a   Dechow, Tobias ^a   Keller, Ulrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F FDG; 18F FLT; Mantle cell lymphoma; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; AGED; AMINO ACID TRANSPORT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; THERAPY EFFECT;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 83755180834     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094698     Document Type: Article

References (20)

1. Williams ME, Connors JM, Dreyling MH, et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2011;52:24-33.
2. Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364-6369. (Pubitemid 46218848)
3. Geisler CH. Front-line treatment of mantle cell lymphoma. Haematologica. 2010;95:1241-1243.
4. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511-518.
5. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
6. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
7. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896-1903.
8. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37-43.
9. Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma. 2008;49:1693-1701.
10. 18F-fluorodeoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37:1633-1642.
11. 18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008;8:159-165.
12. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
13. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
14. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
15. 18F]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
16. 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690-696.
17. 18F]fluorothymidine-positron emission tomography in highgrade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
18. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-11061. (Pubitemid 44877006)
19. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197. (Pubitemid 37443390)
20. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215-3223.